Bempedoic acid for statin intolerant patients? This trial is the first positive outcomes trial for this lipid lowering drug — and the FIRST to show non-statin benefit in primary prevention. CLEAR Outcomes Trial, NEJM 2023 ♥️

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia ca.finance.yahoo.com/news/bempedoic… via Yahoo

Good news for Neuland Labs.

USFDA has approved Esperion's new label expansions for NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) for cardiovascular risk reduction

More than 70 million patients to now be eligible for NEXLETOL and NEXLIZET in US

#neulandlabs

My target LDL for high risk recurrent MACE patients; LDL <30
Hard to achieve with oral meds
But some do achieve
60 y / 👵 recurrent mace and DM
Atorvastatin 80 with Bempedoic acid
—> Ldl<10 💪

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia.
Read more here: bit.ly/3UMYuTs

#يحدث_الآن

⚡️Join us in exploring the article exploring the efficacy of Bempedoic acid in reducing major adverse cardiovascular events in statin- intolerant patients✨💫

Topic : Article Alert Topic 3: Bempedoic Acid and Cardiovascular Outcomes In Statin-Intolerant Patients

By

$ESPR Bempedoic Acid - expanded label- CEO says June 01- 3 major payers now on board covering 40 M patients. Insurance denial was an issue. That will go way now.

New program ASPN pharmacy going well. Told many reversals already, some claims going through the very first time.👀

☀️Blue Jet Healthcare 💊

🚨 Big News Alert: Blue Jet Healthcare & Esperion's FDA Approval.

Exciting news as Esperion's bempedoic acid gets FDA approval for label expansion, with Blue Jet Healthcare as the key supplier. Here's why it's a game-changer:

1. Market Expansion:

شوف / شوفي كمية الدراسات (من أيام التسعينيات ابتداء بدراسة 4S المشهوره) التي اثبتت فعالية أدوية الكولسترول 💊 أو 💉 والتي تقلل من أمراض شرايين القلب عن طريق التقليل من ارتفاع مستوى الكوليسترول الضار LDL في الدم !!..
Statins
Ezetimibe
Bempedoic acid
PCSK9-i
Inclisiran

Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex #CLEAR Outcomes

👉 Irrespective of sex, similar efficacy and tolerability with bempedoic acid 🆚placebo
👉bempedoic acid an important option for healthcare providers and patients to reduce CV risk
#ACC24

📁

The US. Food and Drug Administration (FDA) has approved an indication for cardiovascular risk reduction and has updated the primary hyperlipidemia indications for bempedoic acid and bempedoic acid/ezetimibe.

Great news! The FDA approved label expansion for bempedoic acid for an indication to reduce risk of MI & coronary revascularization in adults unable to take recommended statin Rx (including those not on statin) with established CVD or primary prevention at high risk for CV event!

🔴Effects of bempedoic acid on markers of inflammation and Lp(a) #2024Review #openaccess

journals.lww.com/co-cardiology/…
#CardioEd #Cardiology #MedEd #ENARM #cardiotwiteros #meded #cardiology #CardioTwitter #CardioEd #medtwitter

$ESPR New reports that 3 major payers are board June 1 to cover bempedoic acid and many moving up their drug tier status non that the label is expanded for both primary& secondary prevention. The only non statin for primary prevention

#CardioTwitter
#Statinintolernce
#Diabetes

Impact of Bempedoic Acid on Total Cardiovascular Events
✅Bempedoic acid was associated with a reduction in risk of:
📍MACE-4 (HR 0.80)
📍MACE-3 (HR, 0.83)
📍myocardial infarction (HR, 0.69)
📍coronary revascularization (HR, 0.78),
jamanetwork.com/journals/jamac…

Our New Meta-Analysis on Bempedoic Acid (BA)
7 RCTs 17,782 participants
-BA significantly reduced:
-LDL cholesterol by 22.5%
-Risk of major heart events (MACE) by 14%
-Risk of non-fatal heart attacks
-Risk of new-onset DM
particularly for statin-in tolerant
#Meded #Cardiology 1/2

Bempedoic acid may decrease and, in some cases, eliminate the use of statin drugs.

Unfortunately, it's very expensive and statins are usually covered.

Recent data have demonstrated that the use of Bempedoic Acid in those who are intolerant to statin therapy

Reduced the number of heart attacks and other vascular events by about 15%.

/10

$ESPR Bempedoic acid success story. It now has a broad label with primary and secondary prevention indications.

Perfect scenario described below for bempedoic acid. Combo pill #Nexlizet did the trick and did not cause muscle pain and did not raise glucose.
#CardioTwitter

Is your practice taking care of patients facing #statin -intolerance? #primarycare

In a long-term study, bempedoic acid (Nexletol) significantly reduced the risk of heart attacks, strokes, and other cardiovascular events (39.9 months). #BempedoicAcid #HeartHealth